Safety of Infliximab Following Live Virus Vaccination in Kawasaki Disease Patients

    loading  Checking for direct PDF access through Ovid

Abstract

No published data are available regarding infliximab use in Kawasaki disease patients with recent live virus vaccination. We investigated 38 acute Kawasaki disease patients who received infliximab within 90 days of receiving measles-mumps-rubella, varicella-zoster virus, or Rotavirus vaccines. There were no adverse events or serious infections, which suggests that infliximab use in acute Kawasaki disease patients with recent live viral vaccinations is safe.

Related Topics

    loading  Loading Related Articles